Abivax SA American Shares (ABVX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Abivax SA American Share... (ABVX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

6.36

0.21 (3.41%)

At close: Jan 15, 2025, 10:28 AM

undefined% (undefined)

Bid	6.28
Market Cap	402.82M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.52
PE Ratio (ttm)	-1.81
Forward PE	n/a
Analyst	Buy

Ask	6.32
Volume	5,190
Avg. Volume (20D)	152,809
Open	6.23
Previous Close	6.15
Day's Range	6.23 - 6.36
52-Week Range	5.54 - 17.02
Beta	undefined

About ABVX

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is h...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 20, 2023

Employees 62

Stock Exchange NASDAQ

Ticker Symbol ABVX

Website https://www.abivax.com

Analyst Forecast

According to 6 analyst ratings, the average rating for ABVX stock is "Buy." The 12-month stock price forecast is $43, which is an increase of 576.10% from the latest price.

Buy 83.33%

Hold 16.67%

Sell 0.00%

Stock Forecasts

News

4 months ago · zacks.com

Is Abivax SA Sponsored ADR (ABVX) Outperforming Other Medical Stocks This Year?

Here is how Abivax SA Sponsored ADR (ABVX) and PetIQ (PETQ) have performed compared to their sector so far this year.

4 months ago · zacks.com

Wall Street Analysts Believe Abivax SA Sponsored ADR (ABVX) Could Rally 193.62%: Here's is How to Trade

The mean of analysts' price targets for Abivax SA Sponsored ADR (ABVX) points to a 193.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme...

9 months ago · seekingalpha.com

ABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call Transcript

ABIVAX Société Anonyme (OTC:AAVXF) Q4 2023 Earnings Conference Call April 8, 2024 8:30 AM ET Company Participants Patrick Malloy - SVP, IR Marc de Garidel - CEO Sheldon Sloan - Chief Medical Officer D...

1 year ago · businesswire.com

Citi Appointed as Depositary Bank for Abivax SA's ADR Program

LONDON--(BUSINESS WIRE)--Citi, acting through Citibank N.A., has been appointed by Abivax SA (“Abivax”), to act as depositary bank for its initial public offering (the “IPO”) of Abivax's American Depo...

1 year ago · seekingalpha.com

U.S. IPO Weekly Recap: Big Launches And New Filings Keep The IPO Market Moving

Both the calendar and the pipeline saw some movement this past week. Two large IPOs launched, one of which also priced, and two sizable deals submitted new filings. Eight IPOs submitted initial filing...

1 year ago · marketwatch.com

Abivax increases size of Nasdaq uplisting deal

Abivax S.A. ABVX, -2.53% has increased the size of its global offering to 20.33 million shares from 18.68 million shares as part of its uplisting to the Nasdaq under the ticker symbol “ABVX” from Euro...

1 year ago · seekingalpha.com

Abivax Readies $250 Million U.S. IPO For Drug Pipeline

Abivax has filed proposed terms to raise $250 million in an IPO to fund the development of its treatment candidates for chronic inflammatory diseases. The company's lead candidate, Obefazimod, is ente...

1 year ago · seekingalpha.com

U.S. IPO Weekly Recap: Birkenstock Missteps In Public Debut

1 year ago · seekingalpha.com

Abivax SA Starts U.S. IPO Process

Abivax SA has filed for a $100 million IPO in the U.S. to raise funds for its pipeline development plans. The company's lead candidate, Obefazimod, is entering Phase 3 clinical trials for Ulcerative C...